BAKER BROS. ADVISORS LP Q2 2016 Filing
Filed August 15, 2016
Portfolio Value
$9.5B
Holdings
135
Report Date
Q2 2016
Filing Type
13F-HR
All Holdings (135 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | —Mast Therapeutics, Inc. | 3,868,026 | $1.8B | 19.06% | |
| 102 | —MediWound Ltd. | 226,000 | $1.8B | 18.69% | |
| 103 | AMRNAmarin Corporation plc | 801,860 | $1.7B | 18.16% | |
| 104 | QUREuniQure N.V. | 230,000 | $1.7B | 17.77% | |
| 105 | ENTAEnanta Pharmaceuticals, Inc. | 75,357 | $1.7B | 17.43% | |
| 106 | —CytRx Corporation | 659,995 | $1.5B | 15.43% | |
| 107 | KPTIEURKaryopharm Therapeutics Inc. | 216,990 | $1.5B | 15.27% | |
| 108 | ASMBAssembly Biosciences, Inc. | 250,000 | $1.4B | 14.55% | |
| 109 | —GW Pharmaceuticals plc | 15,000 | $1.4B | 14.41% | |
| 110 | ISIIonis Pharmaceuticals, Inc. | 57,140 | $1.3B | 13.95% | |
| 111 | CLLSCellectis S.A. | 50,000 | $1.3B | 13.94% | |
| 112 | —Immune Design Corp. | 148,937 | $1.2B | 12.74% | |
| 113 | DVAXDynavax Technologies Corporation | 75,000 | $1.1B | 11.47% | |
| 114 | —Tenax Therapeutics, Inc. | 420,000 | $1.1B | 11.27% | |
| 115 | SCYXEURSCYNEXIS, Inc. | 467,600 | $1.0B | 10.64% | |
| 116 | —Affimed N.V. | 400,000 | $992.0M | 10.40% | |
| 117 | XLRNAcceleron Pharma Inc. | 28,765 | $977.0M | 10.24% | |
| 118 | —Palatin Technologies, Inc. | 2,050,000 | $905.0M | 9.49% | |
| 119 | ADAPYAdaptimmune Therapeutics plc | 100,000 | $815.0M | 8.54% | |
| 120 | ALDXAldeyra Therapeutics, Inc. | 142,000 | $808.0M | 8.47% | |
| 121 | —Five Prime Therapeutics, Inc. | 19,247 | $796.0M | 8.35% | |
| 122 | ALNYAlnylam Pharmaceuticals, Inc. | 11,340 | $629.0M | 6.59% | |
| 123 | I9DNArbutus Biopharma Corporation | 180,582 | $628.0M | 6.58% | |
| 124 | —Ritter Pharmaceuticals, Inc. | 400,000 | $612.0M | 6.42% | |
| 125 | —Synta Pharmaceuticals Corp. | 2,021,728 | $526.0M | 5.51% | |
| 126 | —BioDelivery Sciences International, Inc. | 210,021 | $496.0M | 5.20% | |
| 127 | —Windtree Therapeutics, Inc. | 254,973 | $492.0M | 5.16% | |
| 128 | CMRXEURChimerix, Inc. | 115,216 | $453.0M | 4.75% | |
| 129 | —ProNAi Therapeutics, Inc. | 200,000 | $398.0M | 4.17% | |
| 130 | —Foundation Medicine, Inc. | 20,892 | $390.0M | 4.09% | |
| 131 | —Achaogen, Inc. | 100,000 | $379.0M | 3.97% | |
| 132 | CCXIEURChemoCentryx, Inc. | 49,064 | $220.0M | 2.31% | |
| 133 | —La Jolla Pharmaceutical Company | 13,746 | $220.0M | 2.31% | |
| 134 | BGMS 6 PERPCyclacel Pharmaceuticals, Inc. | 13,253 | $83.0M | 0.87% | |
| 135 | —BioTime, Inc. | 20,084 | $9.0M | 0.09% |
PreviousPage 2 of 2